Valuation: TransMedics Group, Inc.

Market Cap 2.29B 2.05B 1.89B 1.71B 3.19B 217B 3.25B 22.48B 9.02B 114B 8.59B 8.4B 360B P/E 2026 *
49.4x
P/E 2027 * 30.2x
Enterprise Value 2.25B 2.01B 1.85B 1.68B 3.14B 213B 3.2B 22.08B 8.87B 112B 8.44B 8.26B 354B EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.45x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week-6.71%
1 month-20.92%
3 months-13.75%
6 months-34.53%
Current year-45.75%
1 week 64.64
Extreme 64.64
71.97
1 month 64.64
Extreme 64.64
84.05
Current year 60.1
Extreme 60.105
151.85
1 year 60.1
Extreme 60.105
156
3 years 38.13
Extreme 38.13
177.37
5 years 10
Extreme 10
177.37
10 years 10
Extreme 10
177.37
Manager TitleAgeSince
Chief Executive Officer 57 01/08/1998
Director of Finance/CFO 46 21/09/2026
Chief Operating Officer 43 02/02/2023
Director TitleAgeSince
Director/Board Member 57 01/08/1998
Chairman 81 01/01/2011
Director/Board Member 78 01/02/2016
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 A Buy

Director

1,336 0.0039%
8/17/26 A Don

Chairman

-18,000 0.0528%
7/10/26 A Free

Chief Financial Officer

43,399 0.1273%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-6.71%-49.83%+76.07% 2.29B
-1.72%+3.44%+22.84%+56.71% 258B
-2.00%+0.75%+7.82%+20.94% 163B
-3.73%-4.48%-19.14%+64.75% 150B
-1.66%-8.12%-58.32%-17.99% 60.84B
-.--%+2.46%-11.69%-7.41% 53.31B
-2.57%+3.30%+11.59%+44.40% 53.03B
+0.84%-3.12%+7.47%+62.40% 50.67B
-3.47%+1.04%+19.48%+69.17% 49.3B
-3.61%+1.99%+32.36%+93.99% 45.46B
Average -1.96%-0.94%-3.74%+46.30% 88.63B
Weighted average by Cap. -2.10%+0.14%+3.89%+44.73%

Financials

2026 *2027 *
Net sales 742M 665M 611M 554M 1.04B 70.47B 1.05B 7.29B 2.93B 37.07B 2.79B 2.73B 117B 875M 783M 721M 653M 1.22B 83.05B 1.24B 8.59B 3.45B 43.69B 3.28B 3.21B 138B
Net income 50.86M 45.55M 41.9M 37.96M 70.96M 4.83B 72.29M 500M 201M 2.54B 191M 187M 8.01B 88.04M 78.85M 72.53M 65.72M 123M 8.36B 125M 865M 347M 4.4B 330M 323M 13.87B
Net Debt -40.26M -36.06M -33.17M -30.05M -56.17M -3.82B -57.22M -396M -159M -2.01B -151M -148M -6.34B -146M -130M -120M -109M -203M -13.83B -207M -1.43B -574M -7.27B -547M -535M -22.94B
Projected Income Statement - Annual - TransMedics Group, Inc.
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
898
Date Price Change Volume
30/10/26 $65.99 -1.68% 900,109
29/10/26 $67.12 +0.33% 991,426
28/10/26 $66.90 -4.06% 1,183,676
27/10/26 $69.73 -1.27% 826,605
26/10/26 $70.63 -0.16% 847,927
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - TransMedics Group, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
65.99USD
Average target price
98.73USD
Spread / Average Target
+49.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TransMedics Group, Inc.
  1. Stock Market
  2. Stocks
  3. TMDX Stock